WO1994005332A3 - Glycolation de macromolecules glycosylees - Google Patents

Glycolation de macromolecules glycosylees Download PDF

Info

Publication number
WO1994005332A3
WO1994005332A3 PCT/US1993/008196 US9308196W WO9405332A3 WO 1994005332 A3 WO1994005332 A3 WO 1994005332A3 US 9308196 W US9308196 W US 9308196W WO 9405332 A3 WO9405332 A3 WO 9405332A3
Authority
WO
WIPO (PCT)
Prior art keywords
macromolecule
macromolecules
polyalkylene glycol
glycosylated
diamino compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/008196
Other languages
English (en)
Other versions
WO1994005332A2 (fr
Inventor
Timkulu Thabiso M
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlex Laboratories Inc
Original Assignee
Berlex Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlex Laboratories Inc filed Critical Berlex Laboratories Inc
Priority to AU50981/93A priority Critical patent/AU5098193A/en
Publication of WO1994005332A2 publication Critical patent/WO1994005332A2/fr
Publication of WO1994005332A3 publication Critical patent/WO1994005332A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un procédé de couplage de glycols à des macromolécules par glycosylations sur ces dernières et non par des groupes amino ou carboxyle sur le squelette de celles-ci. On produit ainsi des macromolécules à réponse immunogène réduite et à activité maintenue. Ledit procédé de glycosylation d'une macromolécule glycosylée consiste à activer un glycol de polyalkylène; à faire réagir le glycol de polyalkylène activé avec un composé diamino, le glycol de polyalkylène activé étant couplé au composé diamino par un de ses groupes amino; à oxyder la macromolécule afin d'activer au moins un groupe glycosyl qu'elle contient; et à faire réagir le glycol de polyalkylène couplé au composé diamino avec le groupe glycosyl oxydé dans la macromolécule. On obtient ainsi une macromolécule glycosylée glycolée dans laquelle le glycol est lié à la macromolécule par ses glycosylations.
PCT/US1993/008196 1992-09-01 1993-09-01 Glycolation de macromolecules glycosylees Ceased WO1994005332A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50981/93A AU5098193A (en) 1992-09-01 1993-09-01 Glycolation of glycosylated macromolecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93777992A 1992-09-01 1992-09-01
US07/937,779 1992-09-01

Publications (2)

Publication Number Publication Date
WO1994005332A2 WO1994005332A2 (fr) 1994-03-17
WO1994005332A3 true WO1994005332A3 (fr) 1994-04-14

Family

ID=25470393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/008196 Ceased WO1994005332A2 (fr) 1992-09-01 1993-09-01 Glycolation de macromolecules glycosylees

Country Status (2)

Country Link
AU (1) AU5098193A (fr)
WO (1) WO1994005332A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
AU721129B2 (en) * 1996-01-08 2000-06-22 Genentech Inc. WSX receptor and ligands
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
DK1007082T3 (da) 1997-01-15 2007-02-19 Phoenix Pharmacologics Inc Modificeret tumor nekrose faktor
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
AU766190B2 (en) 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
DK1656952T3 (da) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
EP2292273A3 (fr) 2001-10-10 2011-11-23 BioGeneriX AG Remodelage et Glycoconjugaison de Peptides
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
MXPA05002594A (es) * 2002-09-11 2005-05-27 Fresenius Kabi Gmbh Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
ES2477118T3 (es) 2002-11-18 2014-07-15 Polaris Group Método para inhibir la replicaci�n viral in vivo
AU2004221824B2 (en) 2003-03-14 2009-08-27 Ratiopharm Gmbh Branched water-soluble polymers and their conjugates
WO2004091499A2 (fr) 2003-04-09 2004-10-28 Neose Technologies, Inc. Formation intracellulaire de conjugues de peptides
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
CA2522345A1 (fr) 2003-04-09 2004-11-18 Neose Technologies, Inc. Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
WO2005012484A2 (fr) 2003-07-25 2005-02-10 Neose Technologies, Inc. Conjugues anticorps-toxines
NZ547168A (en) 2003-11-24 2010-05-28 Biogenerix Ag Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP1694351A2 (fr) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Hormone stimulant le follicule humain glycopegyle
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
CA2565414A1 (fr) 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag Glycoformes de polypeptides o-liees et leur procede de fabrication
WO2006010143A2 (fr) 2004-07-13 2006-01-26 Neose Technologies, Inc. Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon [glp-1]
WO2006031811A2 (fr) 2004-09-10 2006-03-23 Neose Technologies, Inc. Interferon alpha glycopegyle
EP1814573B1 (fr) 2004-10-29 2016-03-09 ratiopharm GmbH Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf)
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
WO2007126808A1 (fr) 2006-03-31 2007-11-08 Baxter International Inc Facteur viii pégylé
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
EP2144923B1 (fr) 2007-04-03 2013-02-13 BioGeneriX AG Méthodes de traitement à l'aide d'un facteur g-csf glycopégylé
WO2008154639A2 (fr) 2007-06-12 2008-12-18 Neose Technologies, Inc. Procédé amélioré pour la production de sucres de nucléotide
US8546328B2 (en) 2007-08-27 2013-10-01 Biogenerix Ag Liquid formulation of G-CSF conjugate
WO2009094172A2 (fr) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Peptides protecteurs de tissu et analogues peptidiques pour la prévention et le traitement de maladies et de troubles associés à un endommagement tissulaire
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
EP2672260A1 (fr) 2008-05-13 2013-12-11 Advanced Liquid Logic, Inc. Procédés, systèmes et dispositifs associés à un positionneur de gouttelettes
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
BR112012001814A8 (pt) 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
EP3081233B1 (fr) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation de protéines autres que des protéines de coagulation sanguine
ES2800983T3 (es) 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
HK1200695A1 (en) 2012-04-16 2015-08-14 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
JP2019523633A (ja) 2016-04-29 2019-08-29 アライム ファーマシューティカルズ,インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006546A1 (fr) * 1988-01-20 1989-07-27 Cetus Corporation Conjugaison d'un polymere avec la proteine csf-1
EP0442724A2 (fr) * 1990-02-13 1991-08-21 Kirin-Amgen, Inc. IL-6 humaine modifiée
WO1993012220A1 (fr) * 1991-12-12 1993-06-24 Berlex Laboratories, Inc. ANTICORPS DE RECOMBINAISON ET CHIMERIQUES CONTRE c-erbB-2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006546A1 (fr) * 1988-01-20 1989-07-27 Cetus Corporation Conjugaison d'un polymere avec la proteine csf-1
EP0442724A2 (fr) * 1990-02-13 1991-08-21 Kirin-Amgen, Inc. IL-6 humaine modifiée
WO1993012220A1 (fr) * 1991-12-12 1993-06-24 Berlex Laboratories, Inc. ANTICORPS DE RECOMBINAISON ET CHIMERIQUES CONTRE c-erbB-2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 103, no. 11, 16 September 1985, Columbus, Ohio, US; abstract no. 84021 *
VERONESE F. ET AL.: "SURFACE MOFIFICATION OF PROTEINS. ACTIVATION OF MONOMETHOXY-POLYETHYLENE GLYCOLS BY PHENYLCHLOROFORMATES AND MODIFICATION OF RIBONUCLEASE AND SUPEROXIDE DISMUTASE.", APPL. BIOCHEM. BIOTECHNOL., vol. 11, no. 2, 1985, pages 141 - 152 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography

Also Published As

Publication number Publication date
AU5098193A (en) 1994-03-29
WO1994005332A2 (fr) 1994-03-17

Similar Documents

Publication Publication Date Title
EP2599503A3 (fr) Conjugués de polymère d'interféron bêta-1A et leurs utilisations
CA2064835A1 (fr) Nouvelle composition complexe emulsifiee
AU4488593A (en) Low diol polyalkylene oxide biologically active proteinaceous substances
AU6099694A (en) Azlactone activated polyalkylene oxides
AU6475394A (en) Silanes with hydrophilic groups, their synthesis and use as surfactants in aqueous media
EP1818342A3 (fr) Antigènes à CLTA-8 de primates purifiés et réactifs correspondants
NZ336961A (en) Polymer blend comprising a polyester, a polyfunctional acid anhydride and a polyhydric alcohol
AU587721B2 (en) Large stub bottles and mated combination unit
AU2755688A (en) Aqueous dispersion of particulate water soluble polymers in polyethylene glycol
AU8575991A (en) Ultrahigh efficiency alkylene oxide catalysts having enhanced stability
CA2323048A1 (fr) Derives de poly(ethylene glycol) avec groupes reactifs proximaux
IE890116L (en) Conjugation of polymer to colony stimulating factor-1
EP0665994A4 (en) Contactless power delivery system.
ZA967712B (en) Polyalkylene ethers as plasticizers and flow aids in poly (1,4-cyclohexanedimethylene terephthalate) resins
CA2190373A1 (fr) Souches de levure
AU4660789A (en) Polypeptide derivatives
AU4216389A (en) Red-shifted phthalocyanine and tetrabenztriazaporphyrin reagents
EP0602845A3 (en) Message dispatching in an event driven architecture.
WO1989008673A3 (fr) Polyesters hydrophiles modifies
GR3034309T3 (en) IFN--g(b) LIQUID FORMULATIONS
AU4323589A (en) Foldable and portable two-wheel motor vehicle
AU8438998A (en) Glycidyl ether aliphatic polyalcohols as coupling agents in anionic polymerization
AU5444494A (en) 1.8''pcmcia compatible drive having two or more disks
ITRM930157A0 (it) Diaframma per modulo di innesto e suo modulo di innesto, in particolare per autoveicoli.
AU3729889A (en) Branched hydroxy-terminated aliphatic polyethers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA